Restenosis after PCI. Part 2: prevention and therapy

The techniques and materials used during percutaneous coronary intervention have advanced considerably over the past 3 decades, yet restenosis remains one of the major drawbacks of this procedure. Many innovative technologies, including drug-eluting stents, with or without specific polymers, and fully biodegradable stents have been and continue to be developed in the search for a safe and effective antirestenosis therapy. Remarkable advances in stent design and nanoparticle delivery systems ('nanovehicles') have already fueled revolutionary changes in the prevention and treatment of in-stent restenosis. In this Review we provide an overview of the latest innovations for optimizing outcomes of coronary stenting, and up-to-date information about prevention and treatment of in-stent restenosis.

[1]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[2]  F. Eberli,et al.  Randomized Comparison of a Titanium-Nitride-Oxide–Coated Stent With a Stainless Steel Stent for Coronary Revascularization: The TiNOX Trial , 2005, Circulation.

[3]  Mansoor Amiji,et al.  Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields , 2010, Proceedings of the National Academy of Sciences.

[4]  I. Alferiev,et al.  Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[6]  Brad S. Hubbard,et al.  In Vitro and In Vivo Characterization of Novel Biodegradable Polymers for Application as Drug-Eluting Stent Coatings , 2010, Journal of biomaterials science. Polymer edition.

[7]  R. Gaspar.  Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. , 2007, Nanomedicine.

[8]  W. Hsueh,et al.  PPARγ and Atherosclerosis , 2001 .

[9]  Gregg W Stone,et al.  Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.

[10]  W. Hsueh,et al.  Effects on Cell Growth and Movement , 2001 .

[11]  Inder Singh,et al.  Clinical outcomes of drug‐eluting versus bare‐metal in‐stent restenosis , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[12]  P. Quax,et al.  Activation of Nuclear Receptor Nur77 by 6-Mercaptopurine Protects Against Neointima Formation , 2007, Circulation.

[13]  I. Palacios,et al.  Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[14]  F. Alfonso.  Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis? , 2010, Journal of the American College of Cardiology.

[15]  G. Klöppel,et al.  Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. , 2007, Journal of the American College of Cardiology.

[16]  P. Serruys,et al.  Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial , 2011, The Lancet.

[17]  Saibal Kar,et al.  Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model , 2010, Circulation. Cardiovascular interventions.

[18]  A. Kastrati,et al.  Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.

[19]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[20]  P. Teirstein,et al.  5-YEAR FINAL RESULTS OF THE SISR (SIROLIMUS-ELUTING STENTS VERSUS VASCULAR BRACHYTHERAPY FOR IN-STENT RESTENOSIS) TRIAL , 2011 .

[21]  A. Íñiguez,et al.  Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. , 2008, Journal of the American College of Cardiology.

[22]  Gd Rotterdam.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:data from a large two-institutional cohort study , 2007 .

[23]  R. D. de Winter,et al.  Nuclear Receptor Nurr1 Is Expressed In and Is Associated With Human Restenosis and Inhibits Vascular Lesion Formation In Mice Involving Inhibition of Smooth Muscle Cell Proliferation and Inflammation , 2010, Circulation.

[24]  C. Grines,et al.  Coronary Stent Restenosis in Patients Treated With Cilostazol , 2005, Circulation.

[25]  Ralf Degenhardt,et al.  Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis , 2009, Circulation.

[26]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[27]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[28]  A. Kastrati,et al.  2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. , 2010, Journal of the American College of Cardiology.

[29]  A. Kamal,et al.  Cilostazol Versus Aspirin for Secondary Prevention of Vascular Events After Stroke of Arterial Origin , 2009, The Cochrane database of systematic reviews.

[30]  Elliot L Chaikof,et al.  Microfabrication and nanotechnology in stent design. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[31]  A. Kastrati,et al.  Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. , 2011, Circulation.

[32]  Inder Singh,et al.  Drug‐eluting stents versus bare‐metal stents for treatment of bare‐metal in‐stent restenosis , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[33]  Patrick W Serruys,et al.  Coronary stents: looking forward. , 2010, Journal of the American College of Cardiology.

[34]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[35]  A. Colombo,et al.  Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. , 2007, American heart journal.

[36]  N. Caplice,et al.  Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". , 2011, Journal of the American College of Cardiology.

[37]  Shile Huang,et al.  Rapamycins: Mechanisms of Action and Cellular Resistance , 2003, Cancer biology & therapy.

[38]  W. Wijns,et al.  Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. , 2008, Journal of the American College of Cardiology.

[39]  Koichi Matsumoto,et al.  Synthetic Pyrrole-Imidazole Polyamide Inhibits Expression of the Human Transforming Growth Factor-β1 Gene , 2005, Journal of Pharmacology and Experimental Therapeutics.

[40]  L. Hillis,et al.  Percutaneous transluminal coronary angioplasty. , 1994, The American journal of the medical sciences.

[41]  Seung‐Jung Park,et al.  Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[42]  O. Hess,et al.  Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. , 2010 .

[43]  Y. Tabata,et al.  Human Placental Ectonucleoside Triphosphate Diphosphohydrolase Gene Transfer via Gelatin-Coated Stents Prevents In-Stent Thrombosis , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[44]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[45]  G. De Luca,et al.  Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans. , 2010, Atherosclerosis.

[46]  P. Serruys,et al.  A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) study. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[47]  Eric Eeckhout,et al.  Treatment of drug‐eluting stent restenosis: An emerging challenge , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[48]  M. Grinstaff,et al.  Bioactive stent surface coating that promotes endothelialization while preventing platelet adhesion. , 2011, Biomacromolecules.

[49]  Y. Yoon,et al.  Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis , 2004, Circulation.

[50]  L. Mauri,et al.  Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. , 2002, The American journal of cardiology.

[51]  Peter Jüni,et al.  Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis , 2009, Circulation.

[52]  M. Costa.  Treatment of drug-eluting stent restenosis. , 2007, American heart journal.

[53]  M. Pencina,et al.  Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry , 2010, Circulation. Cardiovascular interventions.

[54]  P. Serruys,et al.  Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[55]  K. Node,et al.  Mobilization of CD34-Positive Bone Marrow–Derived Cells After Coronary Stent Implantation: Impact on Restenosis , 2007, Circulation.

[56]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[57]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[58]  D. Hoyt.  Looking forward. , 2011, Bulletin of the American College of Surgeons.

[59]  P. Smits,et al.  2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). , 2011, Journal of the American College of Cardiology.

[60]  F. Eberli,et al.  TCT-44 LEADERS: 5-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer- Final report of the LEADERS study , 2012 .

[61]  T. Matsuda,et al.  Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. , 2003, Biomaterials.

[62]  M. Klomp,et al.  Design and rationale of the TRI-stent adjudication study (TRIAS) program. , 2009, American heart journal.

[63]  I. Seong,et al.  Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). , 2008, Journal of the American College of Cardiology.

[64]  K. Healy,et al.  Peri-implant bone formation and implant integration strength of peptide-modified p(AAM-co-EG/AAC) interpenetrating polymer network-coated titanium implants. , 2007, Journal of biomedical materials research. Part A.

[65]  Ulrike Stampfl,et al.  Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F Nanocoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model , 2008, CardioVascular and Interventional Radiology.

[66]  U. Christians,et al.  The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK Study , 2011, European Journal of Clinical Pharmacology.

[67]  D. Desilvey.  Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. , 2007, The American journal of geriatric cardiology.

[68]  B. Gersh.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2009 .

[69]  Koichi Matsumoto,et al.  A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. , 2009, Cardiovascular research.

[70]  A. Kastrati,et al.  Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. , 2009, European heart journal.

[71]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[72]  A. Colombo,et al.  Drug-eluting stent restenosis the pattern predicts the outcome. , 2006, Journal of the American College of Cardiology.

[73]  A. Yeung,et al.  Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial , 2002, The Lancet.

[74]  U. Christians,et al.  The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK study , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[75]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[76]  F. Prati,et al.  First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. , 2009, JACC. Cardiovascular interventions.

[77]  G. Schuler,et al.  DE NOVO CORONARY LESIONS TREATED WITH THE NOVEL POLYMER-FREE BIOLIMUS-A9 COATED STENTS: 12-MONTH ANGIOGRAPHIC RESULTS FROM THE PROSPECTIVE RANDOMIZED MULTICENTER BIOFREEDOM CLINICAL TRIAL , 2011 .

[78]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[79]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[80]  M. Pfisterer,et al.  A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[81]  A. Kastrati,et al.  Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. , 2003, Journal of the American College of Cardiology.

[82]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[83]  G. Vetrovec,et al.  Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[84]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[85]  Peter Jüni,et al.  Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. , 2011, JACC. Cardiovascular interventions.

[86]  G. Richardt,et al.  INTERNATIONAL FIRST IN MAN TRIAL WITH A NOVEL DRUG ELUTING BALLOON IN PATIENTS PRESENTING WITH IN-STENT RESTENOSIS (PEPPER) , 2011 .

[87]  V. Falk,et al.  The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developedwiththespecial contribution of theEuropeanAssociationof Percutaneous Cardiovascular Interventions (EAPCI) , 2014 .

[88]  Martin Oberhoff,et al.  Stent-Based Delivery of Tissue Inhibitor of Metalloproteinase-3 Adenovirus Inhibits Neointimal Formation in Porcine Coronary Arteries , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[89]  J. Mehilli,et al.  Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results , 2009, Heart.

[90]  L. Bentivoglio.  Percutaneous transluminal coronary angioplasty. , 1979, Annals of internal medicine.

[91]  Xiaohong Liu,et al.  Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors , 2003, Nature.

[92]  M. Joner,et al.  Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis , 2011, Thrombosis and Haemostasis.

[93]  A. Wieczorek,et al.  Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. , 2007, Journal of the American College of Cardiology.

[94]  T. Vahlberg,et al.  Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. , 2010, International journal of cardiology.

[95]  M. Amiji,et al.  Nanoparticulate carriers for the treatment of coronary restenosis , 2007, International journal of nanomedicine.

[96]  Chi‐Hang Lee,et al.  Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infarction: one year follow-up. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[97]  Mitchell W. Krucoff,et al.  A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. , 2008, Journal of the American College of Cardiology.

[98]  M. Kimura,et al.  A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[99]  R. Whitbourn,et al.  COMPARISON OF IN VIVO ECCENTRICITY AND SYMMETRY INDICES BETWEEN METALLIC STENTS AND BIORESORBABLE VASCULAR SCAFFOLDS: INSIGHTS FROM THE ABSORB AND SPIRIT TRIALS , 2011 .

[100]  Koichi Matsumoto,et al.  Novel Gene Silencer Pyrrole-Imidazole Polyamide Targeting Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Attenuates Restenosis of the Artery After Injury , 2008, Hypertension.

[101]  M. Amiji,et al.  Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis , 2010, Biomedical engineering online.

[102]  G. Stone,et al.  Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. , 2008, The American journal of cardiology.

[103]  A. Kastrati,et al.  Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial , 2004, Circulation.

[104]  A. Kastrati,et al.  Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. , 2009, JACC. Cardiovascular interventions.

[105]  A. Kastrati,et al.  [Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial]. , 2012, Vestnik rentgenologii i radiologii.

[106]  K. Sunagawa,et al.  Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[107]  W. Rottbauer,et al.  Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease , 2011, Heart.

[108]  D. Barclay,et al.  One-year follow-up , 1975 .

[109]  R. Virmani,et al.  The bioabsorption process: tissue and cellular mechanisms and outcomes. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[110]  J. Jukema,et al.  Restenosis after PCI. Part 1: pathophysiology and risk factors , 2012, Nature Reviews Cardiology.

[111]  J. Jukema,et al.  Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. , 2001, European heart journal.

[112]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[113]  P. Lin,et al.  Rheolytic Pharmacomechanical Thrombectomy in Experimental Chronic Deep Vein Thrombosis: Effect of L-Arginine on Thrombogenicity and Endothelial Vasomotor Function , 2007, World Journal of Surgery.

[114]  Krzysztof Milewski,et al.  Development of a Novel Prohealing Stent Designed to Deliver Sirolimus From a Biodegradable Abluminal Matrix , 2010, Circulation. Cardiovascular interventions.

[115]  J. Ormiston,et al.  First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[116]  Gregg W Stone,et al.  A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.

[117]  W. Hsueh,et al.  PPARgamma and atherosclerosis: effects on cell growth and movement. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[118]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[119]  Katrin Sternberg,et al.  Biodegradable Sirolimus-loaded Poly(lactide) Nanoparticles as Drug Delivery System for the Prevention of In-Stent Restenosis in Coronary Stent Application , 2011, Journal of biomaterials applications.

[120]  R. Virmani,et al.  A novel paclitaxel‐eluting porous carbon–carbon nanoparticle coated, nonpolymeric cobalt–chromium stent: Evaluation in a porcine model , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[121]  A. Kastrati,et al.  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.

[122]  Raimund Erbel,et al.  Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.

[123]  M. Falagas,et al.  Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. , 2007, American Heart Journal.

[124]  A. Kastrati,et al.  Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. , 2009, JACC. Cardiovascular interventions.

[125]  K. Kichikawa,et al.  Pharmacologic Treatment of Intimal Hyperplasia After Metallic Stent Placement in the Peripheral Arteries: An Experimental Study , 1995, Investigative radiology.

[126]  Bernard Chevalier,et al.  Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[127]  Bernard Chevalier,et al.  A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. , 2010, JACC. Cardiovascular interventions.

[128]  J. Kalus,et al.  Addition of Cilostazol to Aspirin and a Thienopyridine for Prevention of Restenosis After Coronary Artery Stenting: A Meta‐Analysis , 2010, Journal of clinical pharmacology.

[129]  A. Buchwald,et al.  Cutting balloon coronary angioplasty—initial clinical experience , 1993, Clinical cardiology.

[130]  Pengfei Guo,et al.  A meta-analysis of randomized controlled trials , 2019, Medicine.

[131]  R. Virmani,et al.  Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. , 2010, JACC. Cardiovascular interventions.

[132]  F. Schmidt.  Meta-Analysis , 2008 .

[133]  J. Jukema,et al.  Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries , 2007, Heart.

[134]  P. Fitzgerald,et al.  A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. , 2010 .

[135]  N. Kipshidze,et al.  Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. , 2004, Journal of the American College of Cardiology.

[136]  H. Bøtker,et al.  Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial , 2010, The Lancet.

[137]  J. Wilcox,et al.  Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. , 2009, Combinatorial chemistry & high throughput screening.

[138]  William Wijns,et al.  Experience with revascularization procedures does matter: low volume means worse outcome. , 2010, European heart journal.

[139]  A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[140]  P. Fitzgerald,et al.  Prospective, Multicenter, Randomized Trial to ssess Efficacy of Pioglitazone on In-Stent eointimal Suppression in Type 2 Diabetes OPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study) , 2022 .

[141]  B. Gersh,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2010 .

[142]  P. Fitzgerald,et al.  A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. , 2010, Journal of the American College of Cardiology.

[143]  F. Crea,et al.  Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). , 2002, Journal of the American College of Cardiology.

[144]  M. Niemelä,et al.  Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction , 2009, Annals of medicine.

[145]  Chi‐Hang Lee,et al.  Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. , 2008, American heart journal.

[146]  P. Serruys,et al.  The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardi , 2010, JACC. Cardiovascular interventions.

[147]  Timothy O'Brien,et al.  Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[148]  J. Wilcox,et al.  The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[149]  P. Serruys,et al.  Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.

[150]  T. Stijnen,et al.  Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. , 2010, European heart journal.